M. Ramdani

Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients’ Profiles With Oxaliplatin-Induced Peripheral Neuropathy

C. Lambert, S. Melnikov, O. Bouché, 2021, Frontiers in Pharmacology.

A phase III study evaluating oral glutamine and transforming growth factor-beta 2 on chemotherapy-induced toxicity in patients with digestive neoplasm.

E. Assenat, P. Déchelotte, P. Bachmann, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial.

M. Ramdani, C. Renou, A. Pariente, 2006, Gastroenterologie clinique et biologique.

[Toxocariasis and functional intestinal disorders. Presentation of 4 cases].

M. Ramdani, A. Konaté, P. Granier, 1996, Gastroenterologie clinique et biologique.

Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).

M. Ychou, E. Assenat, Y. Bécouarn, 2013 .

Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial.

P. Bachmann, M. Vasson, F. Kwiatkowski, 2014, Clinical nutrition.

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.

P. Couzigou, M. Ducreux, C. Borel, 2018, European journal of cancer.

Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.

I. Sobhani, O. Boulat, O. Bouché, 2017, European journal of cancer.

Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.

O. Bouché, M. Ramdani, J. Seitz, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

O. Bouché, N. Kerckhove, M. Selvy, 2020, Journal of clinical medicine.

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis

C. Lepage, G. Deplanque, V. Bourcier, 2021, Hepatology International.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

M. Ychou, E. Assenat, Y. Bécouarn, 2019, British Journal of Cancer.

Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial

M. Ychou, E. Assenat, Y. Bécouarn, 2019, British Journal of Cancer.

Management of the Zenker diverticulum: multicenter retrospective comparative study of open surgery and rigid endoscopy versus flexible endoscopy

P. Pouderoux, M. Ramdani, R. Garrel, 2023, Surgical Endoscopy.